RSNA: Anxiety May Hasten Progression to Alzheimer Disease
WEDNESDAY, Nov. 25, 2020 -- Apolipoprotein E4 (ApoE4) genotype, anxiety, and lower hippocampal (HV) and entorhinal cortex volumes (ERV) are associated with an elevated progression rate from mild cognitive impairment (MCI) to Alzheimer disease (AD), according to a study scheduled for presentation at the annual meeting of the Radiological Society of North America, held virtually from Nov. 29 to Dec. 5.
Jenny L. Uber, from the Medical University of South Carolina in Charleston, and colleagues examined the effect of anxiety and depression on progression of MCI to AD in a population of 339 patients (mean age, 72 years) with a baseline diagnosis of MCI. Of these patients, 72 and 267 progressed to AD and remained stable, respectively.
The researchers found that among MCI patients with and without progression to AD, there was no difference in age, gender, or years of education. Significantly lower normalized HV and ERV, greater frequency of the ApoE4 allele, and greater maximum levels of anxiety and depression were seen for patients who progressed to AD. An increased rate of progression from MCI to AD was seen in association with the presence of ApoE4, a higher level of anxiety, and lower HV and ERV.
"We need to better understand the association between anxiety disorders and cognitive decline," a coauthor said in a statement. "If we were able in the future to find that anxiety is actually causing progression, then we should more aggressively screen for anxiety disorders in the elderly."
© 2021 HealthDay. All rights reserved.
Posted: November 2020
Read this next
WEDNESDAY, Jan. 20, 2021 -- Nearly one-quarter of physicians report being personally attacked on social media, according to a research letter published online Jan. 4 in JAMA...
TUESDAY, Jan. 19, 2021 -- Parents recognize the potential benefits of peer support programs for mental health in schools but have some concerns, according to the C.S. Mott...
FRIDAY, Jan. 15, 2021 -- Individuals with primary progressive aphasia (PPA) associated with Alzheimer disease (AD) have longitudinally preserved episodic memory, according to a...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.